Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
NCT06853145Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperpolarized xenon gas in idiopathic pulmonary fibrosis (IPF), sponsored by University of Virginia. Primary endpoint: Ventilation effect of HXe129 MRI at 24 hours. Started May 2025; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06853145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853145.